PARIS (Agefi-Dow Jones)–Sanofi and biopharmaceutical company Innovent Biologics have entered into a strategic collaboration agreement to intensify the development and commercialization of new medicines for cancer patients in China.
This agreement aims in particular to evaluate during clinical trial programs the combination of two of Sanofi’s priority active ingredients in oncology, tusamitamab ravtansine and SAR444245, with sintilimab developed by Innovent and Eli Lilly, in the treatment of some of the most common solid tumors in this country, Sanofi said in a statement.
“In addition to this collaboration and this license agreement, Sanofi will invest 300 million euros in the capital of Innovent by subscribing to new ordinary shares,” the group said.
-Francois Schott, Agefi-Dow Jones; 01 41 27 47 92; [email protected] ed: LBO
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
August 04, 2022 11:57 ET (15:57 GMT)